Akeso's Cadonilimab Outperforms PD-1 Inhibitors In Gastric Cancer; Stock Up

Akeso's cadonilimab demonstrated superior first-line efficacy versus a PD-1 inhibitor in advanced gastric/GEJ cancer at ASCO GI, improving median overall survival in PD-L1-low patients to 14.3 months versus 10.3 months (a 51% reduction in risk of death) and showing an objective response rate of 73.3% versus 57.1%. Cadonilimab is already approved for multiple oncology indications, Akeso is advancing head-to-head Phase III registration trials, and both cadonilimab and Ivonescimab were added to China's updated National Reimbursement Drug List effective Jan 1, 2026. The combination of positive clinical readouts, regulatory/reimbursement wins in China and ongoing Phase III programs supports a favorable commercial outlook; AKESO (9926.HK) traded at HK$123.40, up 2.32%, after a 52-week range of HK$55.10–HK$179.

Analysis

Market structure: Akeso (9926.HK / AKESF) is an immediate beneficiary — cadonilimab's superior OS (14.3 vs 10.3 months in PD-L1-low) and 73.3% ORR vs 57.1% implies expansion of treatable patient pool and bargaining power with payers in China after NRDL entry (effective Jan 1, 2026). Primary losers are incumbent PD‑1 monotherapy franchises in gastric/GEJ (pricing pressure in China) and smaller domestic PD‑1 players who lack a CTLA-4 combo. Expect share gains in hospital formularies over 6–24 months; pricing will trade volume for margin due to NRDL ceilings.

Risk assessment: Tail risks include a Phase III head‑to‑head failure, late safety (CTLA‑4 toxicities) revelations, or NRDL re‑pricing — each could cut valuation by >30% in adverse scenarios. Time horizons: immediate (days) — sentiment/volatility pop; short (3–12 months) — commercial uptake and Q1 2026 sales cadence; long (12–36 months) — Phase III/regulatory outcomes. Hidden dependency: revenue hinges on hospital tender dynamics, manufacturing scale‑up and physician uptake in PD‑L1‑low cohorts.

Trade implications: Direct play is a sized long in 9926.HK to capture commercialization and Phase III upside while hedging regulatory risk; use 6–12 month call spreads on AKESF/9926.HK to cap premium. Consider a relative trade long 9926.HK vs short Innovent (1801.HK) to express cadonilimab superiority in gastric cancer in China. Rotate modestly toward China oncology small/mid caps and trim global incumbents with heavy gastric exposure over 12–24 months.

Contrarian angles: The market may underprice NRDL’s margin compression — volume replaces price, so profit expansion is not guaranteed; historical PD‑1 + CTLA‑4 launches (e.g., nivolumab+ipilimumab mix) show uptake can be limited by toxicity and narrow labels. If Phase III endpoints are stricter or payers restrict use to subgroups, upside is capped; conversely, successful global registration would materially re‑rate valuation beyond current levels.

Key Decisions for Investors

• Establish a 2–3% long position in 9926.HK (Akeso) at up to HK$125; add to 4–5% notional if price retraces to HK$110 or below. Place a stop-loss at -15% from entry and plan to take 50% profits on a +25% move or upon a positive Phase III interim/registration filing (12–18 months).
• Buy a 6–12 month call‑spread on AKESF/9926.HK sized for 1–2% portfolio risk: long a near‑ATM call and sell a call 30–50% above current to limit premium. Rationale: leveraged exposure to commercialization/Phase‑III progress while capping downside premium decay.
• Implement a pair trade: long 9926.HK (notional 1–2%) vs short 1801.HK (Innovent) notional sized to net delta neutral (approx equal notional) to express cadonilimab clinical advantage in gastric cancer over 6–18 months. Close the pair if Akeso QoQ NRDL‑driven sales growth <5% for two consecutive quarters.
• Trim 1–1.5% exposure to MRK (Merck) or other global PD‑1 incumbents if biotech weighting >8%: expect incremental pricing pressure in China on gastric PD‑1 franchises over 12–36 months. Reassess after Phase‑III readouts or if Akeso reports sustained safety/tolerability issues within 3 months.